Amrize (NYSE:AMRZ) Stock Gets Price Target Reduction from Oppenheimer

Amrize (NYSE:AMRZ) had its price objective reduced by Oppenheimer from $55.00 to $52.00 in a report released on Monday morning,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also issued reports about the stock. Zacks Research lowered shares of Amrize from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 19th. Royal Bank Of Canada lowered their price objective on shares of Amrize from $48.00 to $32.00 and set an “underperform” rating for the company in a research note on Friday, October 9th. Barclays lowered their price objective on shares of Amrize from $55.00 to $40.00 and set an “equal weight” rating for the company in a research note on Monday, October 19th. DA Davidson lifted their price objective on shares of Amrize from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, October 30th. Finally, Citigroup cut their target price on shares of Amrize from $58.00 to $50.00 and set a “buy” rating on the stock in a research note on Friday, October 2nd. Eight investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $49.06.

Amrize Price Performance

AMRZ stock opened at $44.23 on Monday. The business’s fifty day moving average price is $39.62 and its 200 day moving average price is $50.41. Amrize has a 12-month low of $35.78 and a 12-month high of $65.94. The company has a current ratio of 1.07, a quick ratio of 0.67 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $24.46 billion, a PE ratio of 20.01, a P/E/G ratio of 1.65 and a beta of 0.04.

Amrize (NYSE:AMRZ) last posted its earnings results on Wednesday, October 28th. The company reported $1.05 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.05. Amrize had a return on equity of 10.02% and a net margin of 9.93%. The firm had revenue of $3.77 billion for the quarter. During the same period in the previous year, the company posted $0.98 EPS. Amrize’s revenue was up 2.6% on a year-over-year basis. On average, sell-side analysts anticipate that Amrize will post 2.30 EPS for the current year.

Amrize Dividend Announcement

The firm also recently disclosed a dividend, which will be paid on Wednesday, November 18th. Stockholders of record on Tuesday, November 10th will be issued a $0.11 dividend. The ex-dividend date is Tuesday, November 10th. Amrize’s dividend payout ratio is presently 4.98%.

Insider Buying and Selling at Amrize

In other Amrize news, Director Jacques Sanche bought 4,150 shares of the business’s stock in a transaction dated Wednesday, August 26th. The shares were acquired at an average price of $45.02 per share, with a total value of $186,833.00. Following the transaction, the director owned 9,766 shares of the company’s stock, valued at approximately $439,665.32. The trade was a 73.90% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Mario Gross bought 3,568 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were acquired at an average price of $46.60 per share, with a total value of $166,268.80. Following the purchase, the insider owned 38,485 shares of the company’s stock, valued at $1,793,401. The trade was a 10.22% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 48,983 shares of company stock worth $2,158,755. 0.54% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Amrize

Several hedge funds have recently added to or reduced their stakes in the stock. Caldwell Sutter Capital Inc. lifted its stake in Amrize by 11.5% in the first quarter. Caldwell Sutter Capital Inc. now owns 2,675 shares of the company’s stock valued at $150,000 after buying an additional 275 shares during the last quarter. Grove Bank & Trust boosted its holdings in shares of Amrize by 2.1% in the third quarter. Grove Bank & Trust now owns 17,477 shares of the company’s stock valued at $653,000 after acquiring an additional 353 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its holdings in shares of Amrize by 4.3% in the second quarter. Norman Fields Gottscho Capital Management LLC now owns 11,515 shares of the company’s stock valued at $614,000 after acquiring an additional 475 shares during the period. Farther Finance Advisors LLC grew its position in shares of Amrize by 3.9% during the third quarter. Farther Finance Advisors LLC now owns 14,506 shares of the company’s stock worth $542,000 after acquiring an additional 543 shares during the last quarter. Finally, Choreo LLC grew its position in shares of Amrize by 4.2% during the third quarter. Choreo LLC now owns 17,713 shares of the company’s stock worth $662,000 after acquiring an additional 706 shares during the last quarter.

About Amrize

Amrize is a North American building-solutions company that supplies materials and products used in residential, commercial and infrastructure construction. Its portfolio includes cement, aggregates, ready-mix concrete, asphalt, roofing systems and other building products.

The company serves customers across the United States and Canada through a network of production facilities, distribution locations and related operations. Its products support applications ranging from roads, bridges and other public infrastructure to commercial buildings and residential construction.

Amrize was formed through the separation of Holcim’s North American business and began trading independently on the New York Stock Exchange under the symbol AMRZ in 2025.